Phase 3 Crohn's disease trials recruiting now

All Crohn's disease trials, every phase

Other phases for Crohn's disease

Phase 3 Crohn's disease trials

• A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)
  NCT06405087 · Phase: Phase 3 · Ages: 2 Years to 17 Years · Sex: All (male and female) · 108 locations
• A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
  NCT06663332 · Phase: Phase 3 · Ages: 3 Years and older · Sex: All (male and female) · 147 locations
• A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
  NCT07184944 · Phase: Phase 3 · Ages: 16 Years to 80 Years · Sex: All (male and female) · 35 locations
• A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
  NCT04844606 · Phase: Phase 3 · Ages: 2 Years to 19 Years · Sex: All (male and female) · 136 locations
• A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
  NCT07499232 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 160 locations
• A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
  NCT05923073 · Phase: Phase 3 · Ages: 2 Years to 17 Years · Sex: All (male and female) · 85 locations
• A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
  NCT07196722 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 370 locations
• A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
  NCT07577843 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 142 locations
• A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
  NCT05509777 · Phase: Phase 3 · Ages: 2 Years to 17 Years · Sex: All (male and female) · 81 locations
• A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
  NCT06227910 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 138 locations
• A Study of Vedolizumab in Adult Participants With Moderate to Severe Crohn's Disease
  NCT05837897 · Phase: Phase 3 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 41 locations
• A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)
  NCT05442567 · Phase: Phase 3 · Ages: 2 Years and older · Sex: All (male and female) · 196 locations
• A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)
  NCT04779320 · Phase: Phase 3 · Ages: 2 Years to 17 Years · Sex: All (male and female) · 96 locations
• A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
  NCT06100289 · Phase: Phase 3 · Ages: 2 Years to 17 Years · Sex: All (male and female) · 108 locations
• A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
  NCT05995353 · Phase: Phase 3 · Ages: 2 Years to 17 Years · Sex: All (male and female) · 85 locations
• A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
  NCT06819891 · Phase: Phase 3 · Ages: 16 Years to 80 Years · Sex: All (male and female) · 199 locations
• A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
  NCT06819878 · Phase: Phase 3 · Ages: 16 Years to 80 Years · Sex: All (male and female) · 374 locations
• A Study to Assess the Pharmacokinetics, Effectiveness and Safety of Afimkibart for Induction and Maintenance Therapy in Children With Moderately to Severely Active Crohn's Disease
  NCT07298421 · Phase: Phase 3 · Ages: 2 Years to 17 Years · Sex: All (male and female) · 14 locations
• A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
  NCT06430801 · Phase: Phase 3 · Ages: 16 Years to 80 Years · Sex: All (male and female) · 499 locations
• An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
  NCT07184931 · Phase: Phase 3 · Ages: 16 Years to 80 Years · Sex: All (male and female) · 301 locations
• Comparison of Azathioprine to Methotrexate in Combination Therapy With Adalimumab in Crohn's Disease: an Open-label Randomized Controlled Trial
  NCT05040464 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
  NCT06332534 · Phase: Phase 3 · Ages: 2 Years to 17 Years · Sex: All (male and female) · 85 locations
• Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)
  NCT06651281 · Phase: Phase 3 · Ages: No age limits stated · Sex: All (male and female) · 74 locations
• Fecal Microbiota Transplantation in Crohn's Disease as Relay After Anti-TNF Withdrawal
  NCT04997733 · Phase: Phase 3 · Ages: 18 Years to 74 Years · Sex: All (male and female) · 1 location
• InDuctIon TREatment with SubCuTaneous Infliximab for Crohn's Disease
  NCT06059989 · Phase: Phase 3 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location
• Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
  NCT06937099 · Phase: Phase 3 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 183 locations
• Modafinil for Debilitating Fatigue in Quiescent Inflammatory Bowel Disease MODIFI-IBD Trial)
  NCT07582458 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 4 locations
• Phase 3 Study of Human TH-SC01 Cell Injection for Treating Perianal Fistulas in Patients With Crohn's Disease
  NCT06925594 · Phase: Phase 3 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• Precise Infliximab Exposure and Pharmacodynamic Control
  NCT05660746 · Phase: Phase 2, Phase 3 · Ages: 6 Years to 22 Years · Sex: All (male and female) · 11 locations
• Testing the Role of Anti-fungal Therapy in Improving the Response to Therapies for Crohn's Disease
  NCT06274554 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Use of Crohn's Disease Exclusion Diet on Top of Standard Therapy Versus Standard Therapy Alone in Unstable Pediatric Crohn's Disease Patients.
  NCT04777656 · Phase: Phase 3 · Ages: 6 Years to 17 Years · Sex: All (male and female) · 4 locations

Common questions

What does Phase 3 mean?

See how clinical trials work.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.